Refine
Has Fulltext
- yes (9) (remove)
Is part of the Bibliography
- yes (9)
Document Type
- Journal article (9)
Language
- English (9) (remove)
Keywords
- positron emission tomography (4)
- CXCR4 (3)
- lymphoma (3)
- chemokine receptor (2)
- in vivo imaging (2)
- microenvironment (2)
- target (2)
- B‐cell lymphoma (1)
- C-Myc (1)
- CXCR4/SDF-1 (1)
- DHAP (1)
- DLBCL (1)
- FDG PET/CT (1)
- FDG-PET (1)
- FLT-PET (1)
- NVP-BGT226 (1)
- PET (1)
- Pentixafor (1)
- Rho-GTPases (1)
- SGN-35 (1)
- USP9X (1)
- XIAP (1)
- [18F]Fluorodeoxythymidine (1)
- acute myeloid leukemia (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anti-CD30 drug conjugate (1)
- apoptosis, Myc (1)
- autologous transplantation (1)
- bone disease (1)
- cancer (1)
- cells (1)
- clinical studies (1)
- combined therapy (1)
- cycle (1)
- early response (1)
- endothelial cells (1)
- growth (1)
- high-dose chemotherapy (1)
- imaging proliferation (1)
- in-vivo (1)
- inhibition (1)
- involvement (1)
- leukemia (1)
- malignancies (1)
- mammalian target of rapamycin (1)
- marrow transplantation (1)
- mitosis (1)
- molecular imaging (1)
- multiple myeloma (1)
- mutations (1)
- niche (1)
- non-hodgkins-lymphoma (1)
- peripheral T-cell (1)
- phosphatidylinositol-3-kinase (1)
- prognostic value (1)
- refractory/relapsed lymphoma (1)
- retrospective studies (1)
- signaling pathway (1)
- solid tumors (1)
- spleen (1)
- stem-cells (1)
- survival (1)
- therapeutic target (1)
- tumor (1)
- ubiquitin (1)
- uptake (1)
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.